Clinical Trials
10 trialsNCT02481830 2023-07-27
CheckMate331
Bristol-Myers Squibb
Phase 3 Completed
NCT00388960 2019-11-19
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT00547651 2019-11-06
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Celgene
Phase 3 Completed
NCT00375193 2019-10-24
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
Celgene
Phase 2 Completed
NCT01364727 2019-04-16
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Stanford University
Phase 2 Completed
NCT01076504 2016-05-05
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00890955 2015-12-23
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
Hoosier Cancer Research Network
Phase 1 Completed
NCT00660504 2014-07-18
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Sumitomo Pharma (Suzhou) Co., Ltd.
Phase 3 Completed
NCT00132054 2013-05-30
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00319969 2009-09-30
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
Celgene
Phase 2 Completed